Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Multivirus-specific T cells Dose Level 1
Multivirus-specific T cells · 1 trial · 1 indication
DLT is defined as acute GvHD grades III-IV within 42 days of the last dose of CTLs, # of patients with Grade 3-5 infusion-related adverse events within 30 days of the last dose of CTLs, and # of patients with Grade 4-5 non-hematological adverse events within 30 days of the last dose of CTLs. GVHD grade III-IV scoring is based on the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) GVHD scoring stamp or equivalent. Grade 3-5 infusion-related adverse events and Grade 4-5 non-hematological adverse events are graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.X.
| Arm | Type | Description |
|---|---|---|
| Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis | EXPERIMENTAL | Cohort 1 prophylaxis: Participants were administrated 5\*10\^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant. |
| Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment | EXPERIMENTAL | Cohort 1 treatment: Participants were administrated 5\*10\^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant. |
| Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis | EXPERIMENTAL | Cohort 2 prophylaxis: Participants were administrated 1\*10\^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant. |
| Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment | EXPERIMENTAL | Cohort 2 treatment: Participants were administrated 1\*10\^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant. |
| Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis | EXPERIMENTAL | Cohort 3 prophylaxis: Participants were administrated 2\*10\^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant. |
| Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment | EXPERIMENTAL | Cohort 3 treatment: Participants were administrated 2\*10\^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant. |
| Name | Type | Description |
|---|---|---|
| Multivirus-specific T cells Dose Level 1 | BIOLOGICAL | The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level. Dose Level One: 5x10\^6 mCTLs/m2 There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL. |
| Multivirus-specific T cells Dose Level 2 | BIOLOGICAL | The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level. Dose Level Two: 1x10\^7 mCTLs/m2 There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL |
| Multivirus-specific T cells Dose Level 3 | BIOLOGICAL | The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level. Dose Level Three: 2x10\^7 mCTLs/m2 There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL |
Inclusion Criteria: Patients will be eligible following any type of allogeneic transplant to receive CTLs as prevention or for early reactivations as defined below. 1. Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral bloo...
Top 8 of 10 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 7 | PHASE3 | Arexvy, Shingrix |
| Sinovac Biotech Ltd. | SVA | 5 | PHASE3 | Low-dose of tetravalent inactivated enterovirus vaccine, low dose Bivalent Enterovirus Vaccine, Inactivated, Enterovirus Type 71 Vaccine, Inactivated, hexavalent reassortant rotavirus attenuated live vaccine |
| Verrica Pharmaceuticals Inc. | VRCA | 4 | PHASE3 | Cantharidin |
| Valneva SE Sponsored ADR | VALN | 5 | PHASE3 | VLA1553 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Bivalent RSV+HMPV protein vaccine |
| Moderna, Inc. | MRNA | 4 | PHASE1 | mRNA-1195.1, mRNA-1195.2, mRNA-1189, mRNA-1195, mRNA-1345 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Inmazeb |
| Dynavax Technologies Corporation | DVAX | 1 | PHASE1 | Z-1018 |
Multivirus-specific T cells is an investigational cell-based therapy being developed for viral infection. It is designed as a rapidly generated multivirus-specific cytotoxic T lymphocyte product intended for prophylaxis and treatment of Epstein-Barr virus, cytomegalovirus, adenovirus, HHV6 and BK virus. It is being developed by Kalaris Therapeutics, Inc. (ticker KLRS).
Multivirus-specific T cells is being studied for viral infection, specifically for the prophylaxis and treatment of Epstein-Barr virus, cytomegalovirus, adenovirus, HHV6 and BK virus. The program is in Phase 1 clinical development and is not approved for commercial use.
Multivirus-specific T cells is developed by Kalaris Therapeutics, Inc., which trades under the ticker KLRS. The company is the sponsor of the Phase 1 program evaluating the therapy in viral infection.
Multivirus-specific T cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
Multivirus-specific T cells has been evaluated in one completed Phase 1 trial, NCT01570283, titled ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus. The trial enrolled 21 participants in the United States and studied viral infection.
Yes. Multivirus-specific T cells is also known as Multivirus-specific T cells Dose Level 1. Both names refer to the same investigational therapy developed by Kalaris Therapeutics, Inc. (KLRS) for viral infection.